| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Curasight A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 11.35 |
| 52 Week High | DKK 22.90 |
| 52 Week Low | DKK 8.16 |
| Beta | 0.087 |
| 11 Month Change | 11.82% |
| 3 Month Change | 4.61% |
| 1 Year Change | -44.90% |
| 33 Year Change | -60.11% |
| 5 Year Change | n/a |
| Change since IPO | -44.09% |
Recent News & Updates
Shareholder Returns
| CURAS | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 3.2% | -1.3% | -3.7% |
| 1Y | -44.9% | 28.1% | 14.7% |
Return vs Industry: CURAS underperformed the Swedish Biotechs industry which returned 28.1% over the past year.
Return vs Market: CURAS underperformed the Swedish Market which returned 14.7% over the past year.
Price Volatility
| CURAS volatility | |
|---|---|
| CURAS Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: CURAS's share price has been volatile over the past 3 months.
Volatility Over Time: CURAS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 4 | Ulrich Krasilnikoff | www.curasight.com |
Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue.
Curasight A/S Fundamentals Summary
| CURAS fundamental statistics | |
|---|---|
| Market cap | DKK 234.75m |
| Earnings (TTM) | -DKK 31.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs CURAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURAS income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 28.43m |
| Gross Profit | -DKK 28.43m |
| Other Expenses | DKK 3.33m |
| Earnings | -DKK 31.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 79.8% |
How did CURAS perform over the long term?
See historical performance and comparison